Review ArticleClinical Review

Preventing Type 2 Diabetes Mellitus

Jeff Curtis and Charlton Wilson
The Journal of the American Board of Family Practice January 2005, 18 (1) 37-43; DOI: https://doi.org/10.3122/jabfm.18.1.37

References

  1. ↵
    Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003; 26: 917–32.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884–90.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Boyle JP, Honeycutt AA, Narayan KMV, et al. Projection of diabetes burden through 2050. Diabetes Care 2001; 24: 1936–40.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investig 1999; 104: 787–94.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 Suppl 1: 5–10.
    OpenUrl
  6. ↵
    Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization Criteria for Hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 1108–12.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KMV. Estimated number of adults with prediabetes in the U.S. in 2000. Diabetes Care 2003; 26: 645–9.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Genuth S, Alberti KG, Bennett P, et al., and Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–7.
    OpenUrlFREE Full Text
  9. ↵
    de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. JAMA 2001; 285: 2109–13.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR. The fasting hyperglycaemia study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997; 46(12 Suppl 1): 56–60.
    OpenUrl
  11. ↵
    Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med 2001; 345: 790–7.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523–9.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Jovanovic L, Pettit DJ. Gestational diabetes mellitus. JAMA 2001; 286: 2516–8.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002; 25: 1862–8.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S11–4.
  16. ↵
    American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27 Suppl 1: S47–54).
  17. ↵
    Liu P, Li Y, Yu H. Relationship between diabetes mellitus, impaired glucose tolerance and age, menopause, pregnancy: a survey of 5153 women in Shenzen. Chin Med J (Engl) 1999; 112: 612–4.
  18. Wu SI, Chou P, Tsai ST. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol 2001; 54: 117–20.
    OpenUrlCrossRefPubMedWeb of Science
  19. Gaspard UJ, Gottal JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995; 21: 171–8.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998; 21: 1589–95.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Knowler WC, Barrett-Connor E, Fowler SE, et al., and Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991; 34: 891–8.
    OpenUrlCrossRefPubMedWeb of Science
  24. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care 1997; 20: 537–44.
    OpenUrlAbstract/FREE Full Text
  25. Mensink M, Feskens EJ, Saris WH, De Bruin TW, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes Relat Metab Disord 2003; 27: 377–84.
    OpenUrlCrossRefPubMedWeb of Science
  26. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5 year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001; 24: 619–24.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–7.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–6.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Saloranta C, Buitard C, Pecher E, et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25: 2141–6.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Schuster D, Gaillard T, Rhinsmith S, Habash D, Osei K. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus; a placebo-controlled, 24-month randomized study. Metabolism 2003; 52: 1211–7.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obes Res 1999; 7: 477–84.
    OpenUrlPubMedWeb of Science
  33. ↵
    Torgerson JS, Sjöström L. The Swedish obsese subjects (SOS) study—rationale and results. Int J Obes Relat Metab Disord 2001; 25 Suppl 1: S2–4.
    OpenUrlPubMed
  34. ↵
    Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350: 2549–57.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796–803.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 1350–4.
    OpenUrl
  37. ↵
    Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–5.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Captopril Prevention Project study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertension 2002; 20: 1879–86.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the estrogen/progestin replacement study. Ann Intern Med 2003; 139: 1–9.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section